Hospital
Littleton Hospital Association
Littleton Hospital Association was paid $5.24M by Medicaid between Jan 2018 and Dec 2024, across 137 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoLITTLETON HOSPITAL ASSOCIATION
LITTLETON, NH 03561
LITTLETON, NH 03561
33aNPI1144223702assigned 05/27/2005
33bProvider typeCritical Access Hospital
28Total paid$5.24M
24GClaims163,049
24DCodes billed137
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in New Hampshire
Rank by total paid#5 of 9
Median peer was paid$5.24M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,868 | $589K | |
| 2019 | 30,579 | $735K | |
| 2020 | 25,931 | $746K | |
| 2021 | 36,880 | $1.20M | |
| 2022 | 26,447 | $1.03M | |
| 2023 | 8,568 | $492K | |
| 2024incomplete | 7,776 | $442K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 13,769 | 10,090 | $1.12M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 9,696 | 6,149 | $1.11M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.9% | 4,126 | 2,985 | $312K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.1% | 11,523 | 7,120 | $267K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.7% | 4,681 | 1,144 | $246K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 387 | 273 | $243K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 1,161 | 772 | $213K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.1% | 615 | 414 | $163K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.5% | 5,221 | 2,240 | $132K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.4% | 1,826 | 1,523 | $128K |
| 71046 | Radiologic examination, chest; 2 views | 2.1% | 4,455 | 3,230 | $110K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 921 | 554 | $110K |
125 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 2,214 | $76K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.4% | 2,012 | $72K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 2,307 | $64K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 845 | $52K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,886 | $50K |
| 80053 | Comprehensive metabolic panel | <1% | 8,677 | $50K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 699 | $44K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,531 | $43K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,527 | $41K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,351 | $35K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,776 | $34K |
| G0378 | Hospital observation service, per hour | <1% | 202 | $32K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,444 | $31K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 536 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,856 | $29K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 948 | $28K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 842 | $25K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 848 | $21K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 905 | $19K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 885 | $18K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 629 | $15K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 775 | $14K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 596 | $14K |
| 80061 | Lipid panel | <1% | 1,286 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,153 | $13K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,238 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 500 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,649 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,390 | $9K |
| 80305 | <1% | 1,647 | $8K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 71 | $8K |
| H0007 | Alcohol and/or drug services; crisis intervention (outpatient) | <1% | 109 | $7K |
| 85027 | <1% | 1,837 | $6K | |
| 80306 | <1% | 868 | $6K | |
| 87088 | <1% | 2,390 | $6K | |
| 83735 | <1% | 2,524 | $6K | |
| 84484 | <1% | 1,864 | $6K | |
| 83690 | <1% | 1,588 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 173 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 777 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 37 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,561 | $5K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 30 | $4K |
| 86850 | <1% | 614 | $4K | |
| 97161 | <1% | 78 | $4K | |
| 72100 | <1% | 101 | $4K | |
| 82607 | <1% | 439 | $4K | |
| A4649 | Surgical supply; miscellaneous | <1% | 60 | $4K |
| 73030 | <1% | 204 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 597 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,926 | $3K |
| 97750 | <1% | 99 | $3K | |
| 87186 | <1% | 663 | $3K | |
| 82728 | <1% | 278 | $3K | |
| 81001 | <1% | 2,061 | $3K | |
| 87077 | <1% | 636 | $3K | |
| 86780 | <1% | 230 | $2K | |
| 80076 | <1% | 419 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 42 | $2K |
| 87070 | <1% | 347 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 100 | $2K |
| 85610 | <1% | 1,423 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 109 | $2K |
| 87653 | <1% | 80 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 41 | $2K |
| 85730 | <1% | 900 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 18 | $1K |
| 83605 | <1% | 388 | $1K | |
| 83880 | <1% | 231 | $1K | |
| 82746 | <1% | 141 | $1K | |
| 85007 | <1% | 1,284 | $1K | |
| 73610 | <1% | 74 | $1K | |
| 83516 | <1% | 75 | $1K | |
| 85652 | <1% | 752 | $1K | |
| 81003 | <1% | 1,476 | $1K | |
| 84466 | <1% | 138 | $1K | |
| 99441 | <1% | 237 | $1K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 136 | $1K |
| 92557 | <1% | 88 | $1K | |
| 86140 | <1% | 284 | $1K | |
| 87340 | <1% | 128 | $949.03 | |
| 86762 | <1% | 87 | $932.66 | |
| 86901 | <1% | 577 | $932.27 | |
| 86900 | <1% | 577 | $929.75 | |
| 83540 | <1% | 200 | $916.29 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 39 | $809.64 |
| 59025 | Fetal non-stress test | <1% | 24 | $789.56 |
| 95806 | <1% | 15 | $738.00 | |
| 86803 | <1% | 75 | $736.40 | |
| 81025 | <1% | 172 | $727.45 | |
| 84703 | <1% | 139 | $677.09 | |
| 81002 | <1% | 292 | $657.98 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 103 | $633.95 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 26 | $460.88 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 22 | $424.63 |
| 95117 | <1% | 38 | $387.52 | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 79 | $386.96 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 23 | $372.62 |
| J2704 | Injection, propofol, 10 mg | <1% | 20 | $369.66 |
| 82950 | <1% | 82 | $331.48 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 19 | $328.30 |
| 87807 | <1% | 41 | $326.71 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 24 | $242.87 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $220.27 |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 69 | $200.00 |
| 73110 | <1% | 58 | $198.52 | |
| 51798 | <1% | 21 | $197.08 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 22 | $175.13 |
| 73564 | <1% | 32 | $156.40 | |
| 73130 | <1% | 52 | $140.02 | |
| 84439 | <1% | 22 | $136.08 | |
| 92556 | <1% | 14 | $135.00 | |
| 80050 | General health panel | <1% | 14 | $108.22 |
| 99442 | <1% | 30 | $106.38 | |
| 87081 | <1% | 27 | $92.50 | |
| 87040 | <1% | 34 | $74.44 | |
| 92567 | <1% | 14 | $68.25 | |
| 92552 | <1% | 14 | $67.50 | |
| V5266 | Battery for use in hearing device | <1% | 17 | $63.00 |
| 73630 | <1% | 14 | $56.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15 | $30.82 |
| 99051 | <1% | 156 | $29.25 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 0% | 422 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 27 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALKER, LESLIE (VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Littleton Hospital Association | Littleton, NH | $38K |
| Littleton Hospital Association | Littleton, NH | $33K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.